Sarcoidosis drug study halted after just 3 patients
NCT ID NCT02134717
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the drug maraviroc could reduce inflammation in the lungs of people with active sarcoidosis. Participants took the drug for 6 weeks and had two lung exams (bronchoscopy) to measure immune cells before and after treatment. Only 3 people enrolled, and the study was stopped early, so no clear conclusions can be drawn.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dorothy P. and Richard P. Simmons center for Interstitial lung Disease at the University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart scans may unlock hidden risks in minority communities
- Can immune profiling unlock the hidden stages of tuberculosis?
- New imaging tracer could spot hidden cancers and fibrosis in one scan
- Home devices may spot lung flare-ups before they become emergencies
- Massive study tracks lung disease progression in 4,000 patients
- 5,000 patients to help unlock secrets of inflammatory heart disease